HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia

Nature Medicine

Volumn 7, Issue 12, 2001, Pages 1327-1331

  Liang, Jun Shan ^a   Distler, Oliver ^a,b   Cooper, David A ^b   Jamil, Haris ^c   Deckelbaum, Richard J ^a   Ginsberg, Henry N ^a   Sturley, Stephen L ^a  

^a Columbia University College of Physicians and and Surgeons ^*  (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; PROTEASOME; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS B; BIOLOGICAL TRANSPORT; CHOLESTEROL ESTERS; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MICE; MICROSOMES, LIVER; MULTIENZYME COMPLEXES; OLEIC ACID; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES; TUMOR CELLS, CULTURED;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MUS MUSCULUS;

EID: 0035661381     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1201-1327     Document Type: Article

References (34)

1. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD 4 cell counts of 200 per cubic millimeter or less
3. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
5. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
6. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
7. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
8. Severe premature coronary artery disease with protease inhibitors
9. Lipoproteins and the pathogenesis of atherosclerosis
10. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells
11. Intracellular degradation of newly synthesized apolipoprotein B
12. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum
13. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70
14. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
15. HIV-1 protease inhibitors. A review for clinicians
16. Apoprotein B 100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence
17. HIV protease inhibitors stimulate hepatic triglyceride synthesis
18. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys
19. Inhibition of hepatic ACAT decreases ApoB secretion in miniature pigs fed a cholesterol-free diet
20. The Diarylthioimidazole, DuP 128, is a potent inhibitor of acyl-CoA:Cholesterol Acyltransferase (ACAT)
21. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
22. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester
23. Very-low-density lipoprotein assembly and secretion
24. Intracellular assembly of VLDL: Two major steps in separate cell compartments
25. Mouse models of atherosclerosis
26. Insulin resistancecardiovascular disease
27. A risk-benefit assessment of HIV protease inhibitors
28. Myocardial infarction in HIV-infected men receiving protease inhibitors
29. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a)
30. Protein serine/threonine phosphatase inhibitors suppress phenobarbital-induced Cyp2b10 gene transcription in mouse primary hepatocytes
31. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B
32. Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein
33. Effect of a dispersion of cholesterol in Triton WR-1339 on acyl CoA: Cholesterol acyltransferase in rat liver microsomes
34. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia